Even though in psoriasis and PsA patients treated with JAKis, the risk of major cardiovascular events and malignancy seems similar to the global population with these diseases [131,132,133], data from a 4-year open label study in rheumatoid arthritis showed increased rates of major cardiovascular events and malignancy with tofacitinib compared to TNF-α inhibitors [140]. This evidence concerns the gene TNF and psoriasis.